GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Enterprise Value

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Enterprise Value : $0.93 Mil (As of Apr. 29, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Innovation Pharmaceuticals's Enterprise Value is $0.93 Mil. Innovation Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.56 Mil. Therefore, Innovation Pharmaceuticals's EV-to-EBIT ratio for today is -0.36.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Innovation Pharmaceuticals's Enterprise Value is $0.93 Mil. Innovation Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.19 Mil. Therefore, Innovation Pharmaceuticals's EV-to-EBITDA ratio for today is -0.42.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Innovation Pharmaceuticals's Enterprise Value is $0.93 Mil. Innovation Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Innovation Pharmaceuticals's EV-to-Revenue ratio for today is .


Innovation Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Innovation Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals Enterprise Value Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.97 130.49 85.16 12.31 9.12

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.31 7.33 8.73 9.12 5.59

Competitive Comparison of Innovation Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Innovation Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Enterprise Value falls into.



Innovation Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Innovation Pharmaceuticals's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as

Innovation Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation Pharmaceuticals  (OTCPK:IPIX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Innovation Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.929/-2.564
=-0.36

Innovation Pharmaceuticals's current Enterprise Value is $0.93 Mil.
Innovation Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Innovation Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.929/-2.19
=-0.42

Innovation Pharmaceuticals's current Enterprise Value is $0.93 Mil.
Innovation Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.19 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Innovation Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.929/0
=

Innovation Pharmaceuticals's current Enterprise Value is $0.93 Mil.
Innovation Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Executives
Arthur Peter Bertolino officer: Pres. & Chief Medical Officer C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness officer: Vice President 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin director C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor director 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter director 7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich director, 10 percent owner, officer: Chief Financial Officer C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon director, 10 percent owner, officer: President-Chief Scient.Officer 10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans director, officer: Chief Executive Officer 17 IRVING PLACE, PELHAM NY 10803

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Headlines

From GuruFocus

Innovation Pharmaceuticals Provides Brilacidin Program Update

By ACCESSWIRE ACCESSWIRE 11-18-2021